ReviewCancers2024

Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors.

Jyoti Malhotra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.